tilavonemab: Clinical Trials

4 trials of tilavonemab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 1 completed. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Terminated 3, Completed 1

Follow tilavonemab: new trials by email Literature Review of tilavonemab trials Research Report on tilavonemab

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
Tilavonemab - Alzheimer's Disease
Phase 2TerminatedAbbVie3642019-03-222022-09-22
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
ABBV-8E12, Placebo solution for IV infusion on Day 15 - Progressive Supranuclear Palsy (PSP)
Phase 2TerminatedAbbVie1422018-01-242021-02-03
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
ABBV-8E12, placebo for ABBV-8E12 - Alzheimer's Disease
Phase 2CompletedAbbVie4532017-01-262022-08-26
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
Placebo, ABBV-8E12 - Progressive Supranuclear Palsy
Phase 2TerminatedAbbVie3782016-12-122021-02-03

Conditions studied

Tauopathies (3)  ·  Alzheimer Disease (2)  ·  Supranuclear Palsy, Progressive (2)  ·  Cognitive Dysfunction (1)  ·  Dementia (1)  ·  Memory Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurodegenerative Diseases (1)  ·  Pick Disease of the Brain (1)

Sponsors

AbbVie (4)

Countries

Australia (4)  ·  Canada (4)  ·  Italy (4)  ·  United States (4)  ·  Spain (3)  ·  Belgium (2)  ·  Denmark (2)  ·  Finland (2)  ·  Japan (2)  ·  New Zealand (2)  ·  Sweden (2)  ·  France (1)  ·  Germany (1)  ·  Netherlands (1)

Results publications

PMID 33609476, PMID 41281734

NIH funding

2016 (2), 2017 (1), 2018 (1)